skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Free Extracts: Biomedtracker Q3 2017 Outlook Report

Simply complete the required fields and download your free copy of this important report. The full report includes:

 

This report comes to you from Biomedtracker, part of the Informa Pharma Intelligence suite of tools. Biomedtracker provides its clients from the pharmaceutical, biotech, and investment industries insight into the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication. Biomedtracker is the leader in providing objective information alongside evidence-based clinical assessments and investment research on pipeline drugs worldwide.

Download your report extract today

  • 21 drugs and their expected catalysts for Q3 2017 
  • The likelihood of Phase/PDUFA review success for each drug 
  • The overall likelihood of approval (LOA) given each drug’s phase, drug class, and disease group 
  • The results of Q2 2017 catalysts 
  • A list of large impact catalysts through Q3 2017, also available as an Excel download

おすすめのニュース&レポート

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Trialtrove: 医療用医薬品の臨床試験情報デ...

    COVID-19 Infographic

    Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.

    Topics Coronavirus

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Biomedtracker Potential Pivots in 2020

    In this infographic, we provide insight into key trials that are expecting developments in the approval process.

    Topics

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...

    2020 Early Outlook Webinar

    By Michael Haydock

    Anticipate the biggest, most impactful expected catalysts of early 2020 with the guidance and insights from Pharma Intelligence. Building off Biomedtracker’s Early 2020 Outlook report, our live webinar will include market context for these upcoming milestones and additional insights from Datamonitor Healthcare’s Therapeutic Area Directors.

    Topics FDA

;

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。